» Articles » PMID: 19581289

Acetylated NPM1 Localizes in the Nucleoplasm and Regulates Transcriptional Activation of Genes Implicated in Oral Cancer Manifestation

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 2009 Jul 8
PMID 19581289
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Nucleophosmin (NPM1) is a multifunctional protein involved in the regulation of centrosome duplication, ribosome biogenesis, genomic stability, histone chaperone function, and transcription. Overexpression of NPM1 is associated with cancers of diverse histological origins. Here, we have found that p300-mediated acetylation of NPM1 modulates its subcellular localization and augments its oncogenic potential. Acetylated NPM1 is predominantly localized in the nucleoplasm, where it associates with transcriptionally active RNA polymerase II. Deacetylation of NPM1 is brought about by human SIRT1 and reduces its transcriptional activation potential. Remarkably, increased levels of acetylated NPM1 were found in grade II and III oral squamous cell carcinoma (OSCC) patient samples. Small interfering RNA (siRNA)-mediated knockdown of NPM1 in an OSCC cell line, followed by microarray analysis and chromatin immunoprecipitation experiments, revealed that some of the genes involved in oral cancer malignancy are regulated by NPM1 and have acetylated NPM1 localized at their promoters. Either suppression of p300 by siRNA or mutation of acetylatable lysine residues of NPM1 resulted in reduced occupancy of acetylated NPM1 on the target gene promoter concomitant with its decreased transcript levels. These observations suggest that acetylated NPM1 transcriptionally regulates genes involved in cell survival and proliferation during carcinogenesis.

Citing Articles

Functions of the native NPM1 protein and its leukemic mutant.

Falini B, Sorcini D, Perriello V, Sportoletti P Leukemia. 2024; 39(2):276-290.

PMID: 39690184 DOI: 10.1038/s41375-024-02476-4.


Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines.

Safa-Tahar-Henni S, Paez Martinez K, Gress V, Esparza N, Roques E, Bonnet-Magnaval F Leukemia. 2024; 39(1):29-41.

PMID: 39472547 PMC: 11717705. DOI: 10.1038/s41375-024-02400-w.


Recent advances in AML with mutated NPM1.

Ishikawa Y, Ushijima Y, Kiyoi H Int J Hematol. 2024; 120(5):556-565.

PMID: 39174699 DOI: 10.1007/s12185-024-03835-8.


Nucleophosmin: A Nucleolar Phosphoprotein Orchestrating Cellular Stress Responses.

Taha M, Ahmadian M Cells. 2024; 13(15.

PMID: 39120297 PMC: 11312075. DOI: 10.3390/cells13151266.


Activation of AMPK inhibits cervical cancer growth by hyperacetylation of H3K9 through PCAF.

Pan B, Liu C, Su J, Xia C Cell Commun Signal. 2024; 22(1):306.

PMID: 38831454 PMC: 11145780. DOI: 10.1186/s12964-024-01687-7.


References
1.
Okuwaki M, Tsujimoto M, Nagata K . The RNA binding activity of a ribosome biogenesis factor, nucleophosmin/B23, is modulated by phosphorylation with a cell cycle-dependent kinase and by association with its subtype. Mol Biol Cell. 2002; 13(6):2016-30. PMC: 117621. DOI: 10.1091/mbc.02-03-0036. View

2.
Leotoing L, Meunier L, Manin M, Mauduit C, Decaussin M, Verrijdt G . Influence of nucleophosmin/B23 on DNA binding and transcriptional activity of the androgen receptor in prostate cancer cell. Oncogene. 2007; 27(20):2858-67. DOI: 10.1038/sj.onc.1210942. View

3.
Grisendi S, Mecucci C, Falini B, Pandolfi P . Nucleophosmin and cancer. Nat Rev Cancer. 2006; 6(7):493-505. DOI: 10.1038/nrc1885. View

4.
Lafon-Hughes L, Di Tomaso M, Mendez-Acuna L, Martinez-Lopez W . Chromatin-remodelling mechanisms in cancer. Mutat Res. 2008; 658(3):191-214. DOI: 10.1016/j.mrrev.2008.01.008. View

5.
Inge L, Rajasekaran S, Wolle D, Barwe S, Ryazantsev S, Ewing C . alpha-Catenin overrides Src-dependent activation of beta-catenin oncogenic signaling. Mol Cancer Ther. 2008; 7(6):1386-97. PMC: 2527861. DOI: 10.1158/1535-7163.MCT-07-2029. View